spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  SPARC trial 

 HSMN NewsFeed - 2 Jun 2008
Data from Satraplatin SPARC Phase 3 Trial in Patients with Hormone-Refractory Prostate Cancer Progressing after Initial Chemotherapy Presented at 44th ASCO Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Feb 2008
GPC Biotech Announces Corporate Restructuring and Provides Pipeline Update
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 31 Oct 2007
GPC Biotech Today Announced Results of Survival Analysis from the SPARC Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 Oct 2007
GPC Biotech and Pharmion Announce Results of Overall Survival Analysis from the Satraplatin Pivotal Phase 3 Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 Oct 2007
Pharmion and GPC Biotech Announce Results of Overall Survival Analysis From the Satraplatin Pivotal Phase 3 Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Jul 2007
GPC Biotech Withdraws Satraplatin NDA Filed for Accelerated Approval
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Jul 2007
FDA Oncologic Drugs Advisory Committee Recommends that FDA Wait for Overall Survival Results from Satraplatin Phase 3 Trial
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 26 Jun 2007
Pharmion Submits European Marketing Authorization Application for Satraplatin in Combination With Prednisone for the Treatment of Patients With Metastatic Hormone-Refractory Prostate Cancer Who Have Failed Prior Chemotherapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Jun 2007
GPC Biotech Announces that Partner Pharmion Submits European Marketing Application for Satraplatin
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Jun 2007
GPC Biotech Announces Partnering Agreement for Satraplatin for Japan with Yakult
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 4 Jun 2007
Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 May 2007
Additional Satraplatin Efficacy Data From Phase 3 SPARC Trial Presented at Annual Meeting of American Urological Association
Biopharmaceuticals Oncology Urology
 HSMN NewsFeed - 16 Apr 2007
FDA Accepts GPC Biotech's Satraplatin NDA for Filing and Grants Priority Review Status
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Mar 2007
Satraplatin Phase 3 SPARC Trial - Additional Data Presented at European Association of Urology Congress
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Mar 2007
Additional Data from Satraplatin SPARC Phase 3 Trial Presented at European Association of Urology Congress
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Feb 2007
Satraplatin Shown to Significantly Reduce Risk of Disease Progression in Advanced Hormone-Refractory Prostate Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Feb 2007
Spectrum Pharmaceuticals Announces Satraplatin Data Presentation at the American Society of Clinical Oncology Prostate Cancer Symposium
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Feb 2007
GPC Biotech Launches Expanded Access Program for Oncology Drug Candidate Satraplatin in the U.S.
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Feb 2007
GPC Biotech Submits NDA for Lead Oncology Drug Candidate Satraplatin
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Feb 2007
Spectrum Pharmaceuticals Announces Completion of NDA Filing for Satraplatin for Hormone Refractory Prostate Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Sep 2006
Spectrum Pharmaceuticals Announces Positive Results of Satraplatin Pivotal Phase 3 Trial in Patients with Hormone-Refractory Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Sep 2006
Pharmion Corporation and GPC Biotech Announce Positive Results from the Satraplatin Pivotal Phase 3 Trial and Achievement of the Progression-Free Survival Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 May 2006
Independent Data Monitoring Board Recommends Expedited Interim Analysis of Overall Survival Data for Satraplatin Phase 3 Trial
Biopharmaceuticals
 HSMN NewsFeed - 16 May 2006
Pharmion Announces Start of Phase 1 Trial Evaluating Satraplatin Plus Xeloda(R) in Patients With Advanced Solid Tumors
Biopharmaceuticals Oncology
Return to NewsFeed  

 Additional items found! 28

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 28 additional stories matching:
SPARC trial
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.